Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer

Journal of Investigative Medicine

Volumn 58, Issue 8, 2010, Pages 957-960

  Reis, Leonardo O ^a   Vieira, Larissa F M ^c   Zani, Emerson L ^c   Denardi, Fernandes ^a   De Oliveira, Laurione C ^b   Ferreira, Ubirajara ^a  

^a Faculty of Medical Science   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c NONE

Author keywords

Chromogranin A; Gleason; High risk; Metastasis; Neuroendocrine; Prognostic factor; Prostate cancer; PSA; Serum; Testosterone

Indexed keywords

CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78651473491     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181f5d610     Document Type: Article

References (36)

1. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6(4):503-519.
2. Abrahamsson PA, Wadstrom LB, Alumets J, et al. Peptide-hormone-and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract. 1986;181(6):675-683.
3. Bonkhoff H, Wernert N, Dhom G, et al. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate. 1991;19(2):91-98.
4. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1993;423(4):291-294. (Pubitemid 23310596)
5. Bonkhoff H, Fixemer T. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype]. Urologe A. 2004;43(7):836-842.
6. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351(15):1488-1490.
7. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12(1):109-117.
8. Komiya A, Suzuki H, Imamoto T, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol. 2009;16(1):37-44.
9. Deftos LJ, Nakada S, Burton DW, et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology. 1996;48(1):58-62.
10. Isshiki S, Akakura K, Komiya A, et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol. 2002;167(2 Pt 1):512-515.
11. Hirano D, Minei S, Sugimoto S, et al. Implications of circulating chromogranin A in prostate cancer. Scand J Urol Nephrol. 2007;41(4):297-301.
12. Berruti A, Mosca A, Porpiglia F, et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol. 2007;178(3 Pt 1):838-843; quiz 1129.
13. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. (Pubitemid 28445094)
14. Taplin ME, George DJ, Halabi S, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005;66(2):386-391. (Pubitemid 41138103)
15. Abrahamsson PA, Falkmer S, Falt K, et al. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". Pathol Res Pract. 1989;185(3):373-380.
16. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells-a new prognostic parameter in prostate cancer. Br J Urol. 1991;68(3):258-262.
17. Hirano D, Okada Y, Minei S, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004;45(5):586-592; discussion 92.
18. Zissimopoulos A, Bantis A, Sountoulides P, et al. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Hell J Nucl Med. 2009;12(3):234-237.
19. Wu XL, Huang KT, Chen W, et al. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer]. Zhonghua Yi Xue Za Zhi. 2009;89(7):472-475.
20. Leibovitch I, Pinthus Y, Sella BA, et al. [Plasma chromogranin-A (CgA)-a potential marker for diagnosis, monitoring and management of prostate cancer patients]. Harefuah. 2006;145(1):25-29, 78.
21. Ranno S, Motta M, Rampello E, et al. The chromogranin-A (CgA) in prostate cancer. Arch Gerontol Geriatr. 2006;43(1):117-126.
22. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer. 2000;88(11):2590-2597.
23. Berruti A, Dogliotti L, Mosca A, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol. 2001;12(suppl 2): S153-S157.
24. Kimura N, Hoshi S, Takahashi M, et al. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol. 1997;157(2):565-568.
25. Ferrero-Pous M, Hersant AM, Pecking A, et al. Serum chromogranin-A in advanced prostate cancer. BJU Int. 2001;88(7):790-796.
26. Sasaki T, Komiya A, Suzuki H, et al. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol. 2005;48(2):224-229; discussion 9-30.
27. Kokubo H, Yamada Y, Nishio Y, et al. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer. Urology. 2005;66(1):135-140.
28. Chuang CK, Wu TL, Tsao KC, et al. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc. 2003;102(7):480-485.
29. Angelsen A, Syversen U, Haugen OA, et al. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate. 1997;30(1):1-6.
30. Cussenot O, Villette JM, Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol. 1996;155(4):1340-1343.
31. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl. 1998;8:18-22.
32. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39(2):135-148.
33. Xing N, Qian J, Bostwick D, et al. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate. 2001;48(1):7-15.
34. Mazzucchelli R, Montironi R, Santinelli A, et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate. 2000;45(1):72-79.
35. Sciarra A, Monti S, Gentile V, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate. 2003;55(3):168-179.
36. Jongsma J, Oomen MH, Noordzij MA, et al. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate. 2002;50(4):203-215.